Tag: aurora kinase b market size

Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.

Aurora Kinase B Market Size Forecast: How Big Could The Market Get By 2030?

The aurora kinase b market has experienced rapid expansion in its size over recent years. It is projected to expand from $1.27 billion in 2025 to reach $1.43 billion by 2026, demonstrating a compound annual growth rate (CAGR) of 12.0%. This historical growth can be linked to several factors, including developments in molecular oncology research, the recognition of aurora kinase b as a target for cancer treatment, the broadening of clinical trial infrastructure, a rise in investment toward targeted cancer therapies, and advances in the creation of kinase inhibitors.

The aurora kinase b market is anticipated to experience significant expansion in the coming years, with projections indicating it will reach $2.22 billion in 2030, demonstrating a compound annual growth rate (CAGR) of 11.7%. This expected growth during the forecast period is primarily driven by factors such as the increasing demand for precision cancer therapeutics, the expansion of personalized medicine approaches, heightened oncology clinical trial activity, rising investments in novel kinase inhibitors, and improved regulatory support for targeted oncology drugs. Key trends influencing this period include the intensifying development of selective aurora kinase b inhibitors, a growing emphasis on combination oncology therapies, the broadening of precision oncology drug pipelines, an escalating focus on mitotic targeted therapies, and more refined biomarker-based patient stratification.

Get A Free Sample Report With In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20496&type=smp&utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Aurora Kinase B Market Opportunity Drivers: What’s Unlocking New Revenue Potential?

The increasing occurrence of cancer is projected to drive the expansion of the aurora kinase B market in the future. Cancer refers to a collection of diseases marked by the unchecked proliferation and dissemination of abnormal cells, capable of invading nearby tissues and spreading to distant body regions. The rise in cancer cases stems from various factors, including an aging demographic, shifts in lifestyle, environmental exposures, and advancements in detection and diagnosis methods. Aurora kinase B plays a crucial role during cell division (mitosis), and its elevated expression is associated with chromosomal instability and the advancement of cancer. Given its participation in tumor cell division, it is frequently a target in cancer treatments. For example, data from the World Health Organization, a Switzerland-based intergovernmental body, in February 2024 indicated approximately 20 million new cancer cases and 9.7 million deaths were reported in 2022. Projections suggest that by 2050, new cancer cases will surpass 35 million, signifying a 77% rise compared to 2022 figures. Consequently, the increasing prevalence of cancer is propelling the growth of the aurora kinase B market.

Aurora Kinase B Market Segmentation: How Does The Market Break Down By Category?

The aurora kinase b market covered in this report is segmented –

1) By Type: AZD-2811, CS-2164, Danusertib, Ilorasertib, NMI-900, Other Types

2) By Application: Anaplastic Large Cell Lymphoma, Kidney Cancer, Lung Cancer, Prostate Cancer, Other Applications

3) By End-User: Hospitals, Research Institutes, Diagnostic Laboratories, Other End-Users

Subsegments:

1) By AZD-2811: Phase I Clinical Trials AZD-2811, Preclinical Development of AZD-2811, AZD-2811 in Combination Therapy, Targeted Cancer Treatment with AZD-2811

2) By CS-2164: Phase II Clinical Trials CS-2164, Preclinical Development of CS-2164, CS-2164 in Targeted Cancer Therapy, CS-2164 Combination Therapy in Clinical Studies

3) By Danusertib: Phase III Clinical Trials Danusertib, Danusertib for Hematological Malignancies, Danusertib for Solid Tumors, Combination Therapy with Danusertib

4) By Ilorasertib: Preclinical Development of Ilorasertib, Ilorasertib in Solid Tumor Treatment, Phase I and II Clinical Trials of Ilorasertib, Ilorasertib in Combination with Chemotherapies

5) By NMI-900: NMI-900 in Early-Stage Clinical Trials, NMI-900 for Targeted Cancer Therapy, Preclinical Studies of NMI-900, NMI-900 Combination Therapy Trials

6) By Other Types: Other Aurora Kinase B Inhibitors in Development, Novel Targeted Aurora Kinase B Drugs, Combination Therapies Involving Aurora Kinase B Inhibitors, Investigational Aurora Kinase B Inhibitors in Oncology

Aurora Kinase B Market Innovation Trends Shaping Future Development

Leading companies operating within the aurora kinase B market are engaged in developing innovative products, such as aurora kinase inhibitors, with the precise aim of targeting and disrupting critical processes involved in cell division. Aurora kinase inhibitors are medications formulated to impede the activity of Aurora kinases, which are vital for cell division, thereby interfering with the proliferation of cancer cells and potentially reducing tumor growth. For instance, in June 2023, Ellipses Pharma, a UK-based biotechnology company, announced that its EP0042, a dual FLT-3 and Aurora kinase inhibitor, received approval from the U.S. Food and Drug Administration (FDA). EP0042 is currently being developed as a treatment for acute myeloid leukemia (AML) and functions as an inhibitor targeting both FLT3 and Aurora kinase. This specific strategy is tailored for AML patients who have developed resistance to FLT3 inhibitors. Research has indicated that the dual inhibition of FLT3 and Aurora kinase can effectively overcome acquired resistance to selective FLT3 inhibition in both in vitro and in vivo studies.

Aurora Kinase B Market Competitive Overview And Top Companies

Major companies operating in the aurora kinase b market are Pfizer Inc., Johnson & Johnson, Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Sanofi SA, Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim International GmbH, Amgen Inc., Astellas Pharma Inc., Promega Corporation, Rigel Pharmaceuticals Inc., Tocris Bioscience, BPS Bioscience Inc., Advenchen Laboratories LLC, Shenzhen Chipscreen Biosciences Co. Ltd., Cyclacel Pharmaceuticals Inc., Sareum Holdings plc

View The Full Aurora Kinase B Market Report:

https://www.thebusinessresearchcompany.com/report/aurora-kinase-b-global-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Aurora Kinase B Market Geographic Landscape: Which Region Dominates Industry Growth?

North America was the largest region in the aurora kinase B market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the aurora kinase b market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Reach Out To Our Team:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.

Aurora Kinase B Market Revenue Growth Supported By A CAGR Of 2.22% Through 2030

The aurora kinase b market has experienced rapid expansion in recent years, with projections indicating an increase from $1.27 billion in 2025 to $1.43 billion in 2026, reflecting a compound annual growth rate (CAGR) of 12.0%. This historical growth has been driven by progress in molecular oncology research, the recognition of aurora kinase b as a viable cancer target, the broadening of clinical trial capabilities, heightened funding directed at targeted cancer treatments, and advancements in the development of kinase inhibitors.

The aurora kinase b market is anticipated to experience significant expansion over the coming years. By 2030, its value is projected to reach $2.22 billion, reflecting a compound annual growth rate (CAGR) of 11.7%. This upcoming growth is driven by several key factors, including a rising need for precision cancer treatments, an increasing adoption of personalized medicine, a surge in oncology clinical trials, heightened funding for novel kinase inhibitors, and more favorable regulatory frameworks for targeted cancer drugs. Among the main developments shaping this forecast period are the accelerated creation of selective aurora kinase b inhibitors, a stronger focus on drug combinations in oncology, the broadening of precision oncology development pipelines, a heightened emphasis on therapies that target mitotic processes, and enhanced patient selection based on biomarkers.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20496&type=smp&utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Aurora Kinase B Market Growth Factors Supporting Long-Term Expansion

The projected expansion of the aurora kinase B market is anticipated to be driven by the growing prevalence of cancer. Cancer encompasses a range of disorders marked by the unregulated proliferation and dissemination of abnormal cells, which can invade adjacent tissues and spread to distant organs throughout the body. The uptick in cancer diagnoses is fueled by an aging demographic, shifts in lifestyle habits, environmental influences, and enhanced screening and diagnostic methods. Aurora kinase B is essential during mitosis, and its elevated expression is associated with genomic instability and the advancement of cancer. Because it plays a key role in tumor cell division, it is frequently pursued as a target in oncological treatments. As an example, in February 2024, data from the World Health Organization, an intergovernmental entity headquartered in Switzerland, revealed approximately 20 million new cancer diagnoses and 9.7 million fatalities in 2022. Projections suggest that by 2050, new cancer cases could surpass 35 million, marking a 77% rise compared to 2022. Consequently, the rising frequency of cancer is fueling the aurora kinase B market’s growth.

Aurora Kinase B Market Segment Breakdown: Which Categories Generate The Most Revenue?

The aurora kinase b market covered in this report is segmented –

1) By Type: AZD-2811, CS-2164, Danusertib, Ilorasertib, NMI-900, Other Types

2) By Application: Anaplastic Large Cell Lymphoma, Kidney Cancer, Lung Cancer, Prostate Cancer, Other Applications

3) By End-User: Hospitals, Research Institutes, Diagnostic Laboratories, Other End-Users

Subsegments:

1) By AZD-2811: Phase I Clinical Trials AZD-2811, Preclinical Development of AZD-2811, AZD-2811 in Combination Therapy, Targeted Cancer Treatment with AZD-2811

2) By CS-2164: Phase II Clinical Trials CS-2164, Preclinical Development of CS-2164, CS-2164 in Targeted Cancer Therapy, CS-2164 Combination Therapy in Clinical Studies

3) By Danusertib: Phase III Clinical Trials Danusertib, Danusertib for Hematological Malignancies, Danusertib for Solid Tumors, Combination Therapy with Danusertib

4) By Ilorasertib: Preclinical Development of Ilorasertib, Ilorasertib in Solid Tumor Treatment, Phase I and II Clinical Trials of Ilorasertib, Ilorasertib in Combination with Chemotherapies

5) By NMI-900: NMI-900 in Early-Stage Clinical Trials, NMI-900 for Targeted Cancer Therapy, Preclinical Studies of NMI-900, NMI-900 Combination Therapy Trials

6) By Other Types: Other Aurora Kinase B Inhibitors in Development, Novel Targeted Aurora Kinase B Drugs, Combination Therapies Involving Aurora Kinase B Inhibitors, Investigational Aurora Kinase B Inhibitors in Oncology

Aurora Kinase B Market Industry Trends Shaping Future Revenue Growth

Key players in the aurora kinase B market are introducing advanced solutions, like aurora kinase inhibitors, with the aim of precisely interfering with essential cell division mechanisms. These inhibitors function by suppressing the activity of Aurora kinases, which play a vital role in mitosis, thus hindering cancer cell growth and possibly slowing tumor development. A notable example occurred in June 2023, when Ellipses Pharma, a biotechnology firm based in the UK, received approval from the U.S. Food and Drug Administration (FDA) for its candidate EP0042. This compound is a dual inhibitor that targets both FLT-3 and Aurora kinase. Developed to address acute myeloid leukemia (AML), EP0042 is particularly intended for patients whose disease has become resistant to FLT3 inhibitors alone. Studies indicate that by inhibiting both FLT3 and Aurora kinase, it is possible to overcome such acquired resistance, as shown in both laboratory experiments and animal models.

Aurora Kinase B Market Key Players And Strategic Industry Positioning

Major companies operating in the aurora kinase b market are Pfizer Inc., Johnson & Johnson, Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Sanofi SA, Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim International GmbH, Amgen Inc., Astellas Pharma Inc., Promega Corporation, Rigel Pharmaceuticals Inc., Tocris Bioscience, BPS Bioscience Inc., Advenchen Laboratories LLC, Shenzhen Chipscreen Biosciences Co. Ltd., Cyclacel Pharmaceuticals Inc., Sareum Holdings plc

Access The Complete Aurora Kinase B Market Report:

https://www.thebusinessresearchcompany.com/report/aurora-kinase-b-global-market-report?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Aurora Kinase B Market Geographic Distribution And Regional Opportunities

North America was the largest region in the aurora kinase B market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the aurora kinase b market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

How Will The Market Value Of The Aurora Kinase B Market Increase Between 2026 And 2030?

The aurora kinase b market size has experienced rapid expansion in recent years. It is anticipated to grow from $1.27 billion in 2025 to $1.43 billion in 2026, achieving a compound annual growth rate (CAGR) of 12.0%. The growth observed in the historic period can be attributed to several factors, including advancements in molecular oncology research, the identification of aurora kinase b as a specific target in cancer therapy, the broadening of clinical trial infrastructure, increased investment in targeted cancer therapies, and progress made in the development of kinase inhibitors.

The aurora kinase b market is poised for substantial growth in the upcoming years. It is projected to achieve a size of $2.22 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 11.7%. This anticipated expansion over the forecast period is primarily driven by factors such as the escalating demand for precision cancer therapeutics, the wider adoption of personalized medicine strategies, an increase in oncology clinical trial activities, growing investments in innovative kinase inhibitors, and improved regulatory support for targeted oncology drugs. Furthermore, significant trends expected during this period include the intensified development of selective aurora kinase b inhibitors, a greater emphasis on combination oncology therapies, the expansion of precision oncology drug pipelines, a rising focus on mitotic targeted therapies, and enhanced biomarker-based patient stratification.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20496&type=smp

What Primary Factors Are Fueling The Expansion Of The Aurora Kinase B Market?

An anticipated increase in cancer cases is projected to boost the expansion of the aurora kinase B market in the future. Cancer encompasses a range of illnesses defined by the unchecked proliferation and dissemination of atypical cells, capable of invading adjacent tissues and spreading to distant areas of the body. The escalating number of cancer diagnoses stems from elements like an aging demographic, shifts in lifestyle, environmental risk factors, and advancements in screening and identification. Aurora kinase B is crucial for cell division (mitosis), and elevated levels of its expression are associated with unstable chromosomes and the advancement of cancer. Given its participation in the division of tumor cells, it is frequently a focus for cancer treatments. For example, in February 2024, the World Health Organization, an intergovernmental body situated in Switzerland, reported approximately 20 million new cancer cases in 2022, alongside 9.7 million fatalities. Projections indicate that by 2050, new cancer cases will surpass 35 million, marking a 77% surge compared to 2022 figures. Consequently, the increasing prevalence of cancer is fueling the expansion of the aurora kinase B market.

Which Segment Groups Define The Aurora Kinase B Market Landscape?

The aurora kinase b market covered in this report is segmented –

1) By Type: AZD-2811, CS-2164, Danusertib, Ilorasertib, NMI-900, Other Types

2) By Application: Anaplastic Large Cell Lymphoma, Kidney Cancer, Lung Cancer, Prostate Cancer, Other Applications

3) By End-User: Hospitals, Research Institutes, Diagnostic Laboratories, Other End-Users

Subsegments:

1) By AZD-2811: Phase I Clinical Trials AZD-2811, Preclinical Development of AZD-2811, AZD-2811 in Combination Therapy, Targeted Cancer Treatment with AZD-2811

2) By CS-2164: Phase II Clinical Trials CS-2164, Preclinical Development of CS-2164, CS-2164 in Targeted Cancer Therapy, CS-2164 Combination Therapy in Clinical Studies

3) By Danusertib: Phase III Clinical Trials Danusertib, Danusertib for Hematological Malignancies, Danusertib for Solid Tumors, Combination Therapy with Danusertib

4) By Ilorasertib: Preclinical Development of Ilorasertib, Ilorasertib in Solid Tumor Treatment, Phase I and II Clinical Trials of Ilorasertib, Ilorasertib in Combination with Chemotherapies

5) By NMI-900: NMI-900 in Early-Stage Clinical Trials, NMI-900 for Targeted Cancer Therapy, Preclinical Studies of NMI-900, NMI-900 Combination Therapy Trials

6) By Other Types: Other Aurora Kinase B Inhibitors in Development, Novel Targeted Aurora Kinase B Drugs, Combination Therapies Involving Aurora Kinase B Inhibitors, Investigational Aurora Kinase B Inhibitors in Oncology

What Trends Are Influencing The Aurora Kinase B Market Outlook?

Leading companies within the aurora kinase B market are actively engaged in developing innovative products, such as aurora kinase inhibitors, designed to specifically target and disrupt critical processes involved in cell division. Aurora kinase inhibitors are medications formulated to block the activity of Aurora kinases, which are essential for cell division, thereby impeding the proliferation of cancer cells and potentially reducing tumor growth. For instance, in June 2023, Ellipses Pharma, a biotechnology company based in the UK, announced the U.S. Food and Drug Administration (FDA) approval for its compound, EP0042, which functions as a dual FLT-3 and Aurora kinase inhibitor. EP0042 is currently being developed as a treatment for acute myeloid leukemia (AML) and operates by targeting both FLT3 and Aurora kinase. This specific approach is crafted for AML patients who have developed resistance to FLT3 inhibitors. Research has demonstrated that the dual inhibition of FLT3 and Aurora kinase can overcome acquired resistance to selective FLT3 inhibition in both in vitro and in vivo settings.

Who Are The Leading Firms Participating In The Aurora Kinase B Market?

Major companies operating in the aurora kinase b market are Pfizer Inc., Johnson & Johnson, Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Sanofi SA, Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim International GmbH, Amgen Inc., Astellas Pharma Inc., Promega Corporation, Rigel Pharmaceuticals Inc., Tocris Bioscience, BPS Bioscience Inc., Advenchen Laboratories LLC, Shenzhen Chipscreen Biosciences Co. Ltd., Cyclacel Pharmaceuticals Inc., Sareum Holdings plc

Access The Complete Aurora Kinase B Market Report:

https://www.thebusinessresearchcompany.com/report/aurora-kinase-b-global-market-report

Which Area Represents The Largest Portion Of The Aurora Kinase B Market?

North America was the largest region in the aurora kinase B market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the aurora kinase b market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Aurora Kinase B Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=20496&type=smp

Browse Through More Reports Similar to the Global Aurora Kinase B Market 2026, By The Business Research Company

Cancer Biologics Market Report 2026

https://www.thebusinessresearchcompany.com/report/cancer-biologics-global-market-report

Skin Cancer Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/skin-cancer-drugs-global-market-report

Pancreatic Cancer Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/pancreatic-cancer-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

By 2030, What Market Size Is The Aurora Kinase B Market Expected To Reach Based On Its 2026 Value?

The aurora kinase b market size has witnessed swift growth over recent years. It is projected to expand from $1.27 billion in 2025 to $1.43 billion in 2026, achieving a compound annual growth rate (CAGR) of 12.0%. This historical increase can be attributed to various factors such as advancements in molecular oncology research, the identification of aurora kinase b as a cancer target, the expansion of clinical trial infrastructure, escalating investment in targeted cancer therapies, and progress in kinase inhibitor development.

The aurora kinase b market size is projected for substantial expansion in the coming years. It is anticipated to reach $2.22 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 11.7%. This growth over the forecast period stems from escalating demand for precision cancer therapeutics, the broadening of personalized medicine approaches, increased activity in oncology clinical trials, rising investments in novel kinase inhibitors, and improved regulatory support for targeted oncology drugs. Significant trends during this period include the accelerated development of selective aurora kinase b inhibitors, a heightened emphasis on combination oncology therapies, the expansion of precision oncology drug pipelines, an increasing focus on mitotic targeted therapies, and enhanced biomarker-based patient stratification.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20496&type=smp

Which Key Factors Are Driving The Aurora Kinase B Market Growth?

The growing occurrence of cancer is predicted to propel the expansion of the aurora kinase B market in the future. Cancer is defined as a range of diseases marked by the uncontrolled proliferation and dissemination of abnormal cells, capable of invading nearby tissues and spreading to other body parts. The increase in cancer cases is attributed to factors like an aging populace, evolving lifestyles, environmental exposures, and enhanced detection and diagnosis. Aurora kinase B is crucial in mitosis, and its overexpression is connected to chromosomal instability and cancer advancement. It is frequently targeted in cancer therapies because of its involvement in tumor cell division. For example, the World Health Organization reported that an estimated 20 million new cancer cases were recorded in 2022, alongside 9.7 million deaths. By 2050, new cancer cases are anticipated to surpass 35 million, representing a 77% increase from 2022. Consequently, the rising incidence of cancer is driving the growth of the aurora kinase B market.

How Are Different Segments Classified In The Aurora Kinase B Market Segment Analysis?

The aurora kinase b market covered in this report is segmented –

1) By Type: AZD-2811, CS-2164, Danusertib, Ilorasertib, NMI-900, Other Types

2) By Application: Anaplastic Large Cell Lymphoma, Kidney Cancer, Lung Cancer, Prostate Cancer, Other Applications

3) By End-User: Hospitals, Research Institutes, Diagnostic Laboratories, Other End-Users

Subsegments:

1) By AZD-2811: Phase I Clinical Trials AZD-2811, Preclinical Development of AZD-2811, AZD-2811 in Combination Therapy, Targeted Cancer Treatment with AZD-2811

2) By CS-2164: Phase II Clinical Trials CS-2164, Preclinical Development of CS-2164, CS-2164 in Targeted Cancer Therapy, CS-2164 Combination Therapy in Clinical Studies

3) By Danusertib: Phase III Clinical Trials Danusertib, Danusertib for Hematological Malignancies, Danusertib for Solid Tumors, Combination Therapy with Danusertib

4) By Ilorasertib: Preclinical Development of Ilorasertib, Ilorasertib in Solid Tumor Treatment, Phase I and II Clinical Trials of Ilorasertib, Ilorasertib in Combination with Chemotherapies

5) By NMI-900: NMI-900 in Early-Stage Clinical Trials, NMI-900 for Targeted Cancer Therapy, Preclinical Studies of NMI-900, NMI-900 Combination Therapy Trials

6) By Other Types: Other Aurora Kinase B Inhibitors in Development, Novel Targeted Aurora Kinase B Drugs, Combination Therapies Involving Aurora Kinase B Inhibitors, Investigational Aurora Kinase B Inhibitors in Oncology

Which Trends Are Influencing Demand In The Aurora Kinase B Market?

Major entities in the aurora kinase B market are developing novel products, such as aurora kinase inhibitors, designed to specifically disrupt crucial processes in cell division. These inhibitors are drugs engineered to block the activity of Aurora kinases, which are critical for cell division, thereby interrupting cancer cell proliferation and potentially reducing tumor growth. For instance, in June 2023, Ellipses Pharma, a UK-based biotechnology company, announced U.S. Food and Drug Administration (FDA) approval for its EP0042, a dual FLT-3 and Aurora kinase inhibitor. EP0042 is under development as a treatment for acute myeloid leukemia (AML) and functions as an inhibitor targeting both FLT3 and Aurora kinase. This strategy is specifically formulated for AML patients who have become resistant to FLT3 inhibitors. Research has demonstrated that dual inhibition of FLT3 and Aurora kinase can overcome acquired resistance to selective FLT3 inhibition both in vitro and in vivo.

Who Are The Companies Driving Activity In The Aurora Kinase B Market?

Major companies operating in the aurora kinase b market are Pfizer Inc., Johnson & Johnson, Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Sanofi SA, Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim International GmbH, Amgen Inc., Astellas Pharma Inc., Promega Corporation, Rigel Pharmaceuticals Inc., Tocris Bioscience, BPS Bioscience Inc., Advenchen Laboratories LLC, Shenzhen Chipscreen Biosciences Co. Ltd., Cyclacel Pharmaceuticals Inc., Sareum Holdings plc

Get The Full Aurora Kinase B Market Report:

https://www.thebusinessresearchcompany.com/report/aurora-kinase-b-global-market-report

Which Region Is The Largest In The Aurora Kinase B Market?

North America was the largest region in the aurora kinase B market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the aurora kinase b market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Aurora Kinase B Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/aurora-kinase-b-global-market-report

Browse Through More Reports Similar to the Global Aurora Kinase B Market 2026, By The Business Research Company

Cancer Biologics Market Report 2026

https://www.thebusinessresearchcompany.com/report/cancer-biologics-global-market-report

Skin Cancer Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/skin-cancer-drugs-global-market-report

Pancreatic Cancer Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/pancreatic-cancer-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Is The Forecasted Market Value Of The Aurora Kinase B Market Across 2026–2030?

The aurora kinase b market has witnessed substantial rapid growth in recent years. This market is projected to expand from $1.27 billion in 2025 to $1.43 billion in 2026, achieving a compound annual growth rate (CAGR) of 12.0%. Historically, this expansion can be linked to advancements in molecular oncology research, the identification of aurora kinase b as a cancer target, the broadening of clinical trial infrastructure, increasing investment in targeted cancer therapies, and progress in kinase inhibitor development.

The aurora kinase b market is anticipated to experience substantial expansion in the coming years, projected to reach $2.22 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 11.7%. This significant growth in the forecast period is primarily driven by factors such as a heightened demand for precision cancer therapeutics, the broadening adoption of personalized medicine approaches, an uptick in oncology clinical trial activity, increased investments in novel kinase inhibitors, and improved regulatory support for targeted oncology drugs. Furthermore, major trends expected during this period include the intensified development of selective aurora kinase b inhibitors, a growing emphasis on combination oncology therapies, the expansion of precision oncology drug pipelines, an increasing focus on mitotic targeted therapies, and better biomarker-based patient stratification.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20496&type=smp

What Major Growth Drivers Are Shaping The Outlook Of The Aurora Kinase B Market?

The increasing occurrence of cancer is projected to boost the expansion of the aurora kinase B market in the foreseeable future. Cancer refers to a collection of illnesses marked by the uncontrolled multiplication and dispersion of atypical cells, which can infiltrate nearby tissues and spread to other parts of the body. The escalation in cancer cases stems from factors like an aging demographic, shifts in lifestyle, exposure to environmental hazards, and enhanced detection and diagnostic methods. Aurora kinase B is vital for mitosis, and its excessive expression is associated with chromosomal instability and the advancement of cancer. Given its involvement in the division of tumor cells, it is frequently a target in cancer treatments. For example, in February 2024, the World Health Organization, an intergovernmental body based in Switzerland, reported approximately 20 million new cancer cases in 2022, alongside 9.7 million fatalities. Projections indicate that by 2050, new cancer cases will surpass 35 million, signifying a 77% surge from 2022 levels. Consequently, the growing prevalence of cancer is propelling the development of the aurora kinase B market.

What Segmentation Levels Are Considered In The Aurora Kinase B Market?

The aurora kinase b market covered in this report is segmented –

1) By Type: AZD-2811, CS-2164, Danusertib, Ilorasertib, NMI-900, Other Types

2) By Application: Anaplastic Large Cell Lymphoma, Kidney Cancer, Lung Cancer, Prostate Cancer, Other Applications

3) By End-User: Hospitals, Research Institutes, Diagnostic Laboratories, Other End-Users

Subsegments:

1) By AZD-2811: Phase I Clinical Trials AZD-2811, Preclinical Development of AZD-2811, AZD-2811 in Combination Therapy, Targeted Cancer Treatment with AZD-2811

2) By CS-2164: Phase II Clinical Trials CS-2164, Preclinical Development of CS-2164, CS-2164 in Targeted Cancer Therapy, CS-2164 Combination Therapy in Clinical Studies

3) By Danusertib: Phase III Clinical Trials Danusertib, Danusertib for Hematological Malignancies, Danusertib for Solid Tumors, Combination Therapy with Danusertib

4) By Ilorasertib: Preclinical Development of Ilorasertib, Ilorasertib in Solid Tumor Treatment, Phase I and II Clinical Trials of Ilorasertib, Ilorasertib in Combination with Chemotherapies

5) By NMI-900: NMI-900 in Early-Stage Clinical Trials, NMI-900 for Targeted Cancer Therapy, Preclinical Studies of NMI-900, NMI-900 Combination Therapy Trials

6) By Other Types: Other Aurora Kinase B Inhibitors in Development, Novel Targeted Aurora Kinase B Drugs, Combination Therapies Involving Aurora Kinase B Inhibitors, Investigational Aurora Kinase B Inhibitors in Oncology

What Trends Are Projected To Affect The Aurora Kinase B Market?

Leading companies within the aurora kinase B market are advancing innovative products, such as aurora kinase inhibitors, with the goal of specifically targeting and disrupting crucial processes involved in cell division. These inhibitors are medications designed to block the activity of Aurora kinases, which are essential for cell division, thereby impeding the proliferation of cancer cells and potentially reducing tumor growth. For instance, in June 2023, Ellipses Pharma, a UK-based biotechnology company, announced the U.S. Food and Drug Administration (FDA) approval for its EP0042, a dual FLT-3 and Aurora kinase inhibitor. EP0042 is currently under development as a treatment for acute myeloid leukemia (AML) and functions by inhibiting both FLT3 and Aurora kinase. This approach is specifically tailored for AML patients who have developed resistance to FLT3 inhibitors. Research has indicated that the dual inhibition of FLT3 and Aurora kinase can overcome acquired resistance to selective FLT3 inhibition in both in vitro and in vivo studies.

Which Leading Firms Are Contributing To The Growth Of The Aurora Kinase B Market?

Major companies operating in the aurora kinase b market are Pfizer Inc., Johnson & Johnson, Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Sanofi SA, Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim International GmbH, Amgen Inc., Astellas Pharma Inc., Promega Corporation, Rigel Pharmaceuticals Inc., Tocris Bioscience, BPS Bioscience Inc., Advenchen Laboratories LLC, Shenzhen Chipscreen Biosciences Co. Ltd., Cyclacel Pharmaceuticals Inc., Sareum Holdings plc

Read the full aurora kinase b market report here:

https://www.thebusinessresearchcompany.com/report/aurora-kinase-b-global-market-report

Which Regions Are Projected To Dominate The Aurora Kinase B Market In The Coming Years?

North America was the largest region in the aurora kinase B market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the aurora kinase b market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Aurora Kinase B Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=20496&type=smp

Browse Through More Reports Similar to the Global Aurora Kinase B Market 2026, By The Business Research Company

Cancer Biologics Market Report 2026

https://www.thebusinessresearchcompany.com/report/cancer-biologics-global-market-report

Skin Cancer Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/skin-cancer-drugs-global-market-report

Pancreatic Cancer Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/pancreatic-cancer-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the aurora kinase b market from 2026–2035 with trusted insights from The Business Research Company

How much larger will the Aurora Kinase B Market be in 2030 compared with 2026?

The aurora kinase b market has experienced substantial growth in its size over recent years. It is projected to increase from $1.27 billion in 2025 to $1.43 billion in 2026, showing a compound annual growth rate (CAGR) of 12.0%. This expansion during the historic period can be attributed to factors such as advancements in molecular oncology research, the identification of aurora kinase b as a cancer target, an expansion of clinical trial infrastructure, increasing investment in targeted cancer therapies, and progress in kinase inhibitor development.

The aurora kinase b market is projected to experience significant expansion in the coming years. By 2030, its valuation is anticipated to reach $2.22 billion, exhibiting a compound annual growth rate (CAGR) of 11.7%. This anticipated growth during the forecast period stems from factors such as a heightened demand for precision cancer treatments, the broadening adoption of personalized medicine strategies, an uptick in oncology clinical trial endeavors, increased capital allocation towards innovative kinase inhibitors, and enhanced regulatory backing for targeted oncology pharmaceuticals. Key trends influencing this period encompass the accelerated development of selective aurora kinase b inhibitors, a greater focus on combination oncology regimens, the enlargement of precision oncology drug development pipelines, an intensified interest in mitotic targeted treatments, and more effective biomarker-based patient selection.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20496&type=smp

What Drivers Are Guiding Growth Patterns In The Aurora Kinase B Market?

The increasing prevalence of cancer is projected to fuel the expansion of the aurora kinase B market moving forward. Cancer refers to a collection of illnesses marked by the uncontrolled multiplication and dispersion of abnormal cells, capable of invading adjacent tissues and spreading to distant parts of the body. The surge in cancer cases can be attributed to elements like an aging demographic, shifts in lifestyle, environmental exposures, and advancements in detection and diagnostic methods. Aurora kinase B holds a crucial function in mitosis, and its excessive expression is associated with chromosomal instability and the advancement of cancer. Given its role in the division of tumor cells, it is frequently a target in cancer treatments. For example, in February 2024, data from the World Health Organization, an intergovernmental body based in Switzerland, revealed approximately 20 million new cancer cases in 2022, alongside 9.7 million fatalities. Projections indicate that by 2050, new cancer diagnoses are anticipated to surpass 35 million, marking a 77% rise compared to 2022 figures. Consequently, the escalating occurrence of cancer is a key impetus for the expansion of the aurora kinase B market.

How Is The Aurora Kinase B Market Divided Into Segments?

The aurora kinase b market covered in this report is segmented –

1) By Type: AZD-2811, CS-2164, Danusertib, Ilorasertib, NMI-900, Other Types

2) By Application: Anaplastic Large Cell Lymphoma, Kidney Cancer, Lung Cancer, Prostate Cancer, Other Applications

3) By End-User: Hospitals, Research Institutes, Diagnostic Laboratories, Other End-Users

Subsegments:

1) By AZD-2811: Phase I Clinical Trials AZD-2811, Preclinical Development of AZD-2811, AZD-2811 in Combination Therapy, Targeted Cancer Treatment with AZD-2811

2) By CS-2164: Phase II Clinical Trials CS-2164, Preclinical Development of CS-2164, CS-2164 in Targeted Cancer Therapy, CS-2164 Combination Therapy in Clinical Studies

3) By Danusertib: Phase III Clinical Trials Danusertib, Danusertib for Hematological Malignancies, Danusertib for Solid Tumors, Combination Therapy with Danusertib

4) By Ilorasertib: Preclinical Development of Ilorasertib, Ilorasertib in Solid Tumor Treatment, Phase I and II Clinical Trials of Ilorasertib, Ilorasertib in Combination with Chemotherapies

5) By NMI-900: NMI-900 in Early-Stage Clinical Trials, NMI-900 for Targeted Cancer Therapy, Preclinical Studies of NMI-900, NMI-900 Combination Therapy Trials

6) By Other Types: Other Aurora Kinase B Inhibitors in Development, Novel Targeted Aurora Kinase B Drugs, Combination Therapies Involving Aurora Kinase B Inhibitors, Investigational Aurora Kinase B Inhibitors in Oncology

Which Trends Are Influencing The Performance And Direction Of The Aurora Kinase B Market?

Companies operating within the aurora kinase B market are actively engaged in creating innovative products, such as aurora kinase inhibitors, specifically to target and interrupt key processes in cellular division. These aurora kinase inhibitors are medications formulated to obstruct the functioning of Aurora kinases, which are vital for cell division, thereby disrupting the rapid growth of cancer cells and potentially curbing tumor expansion. For example, in June 2023, Ellipses Pharma, a biotechnology firm based in the UK, announced that its EP0042, a dual FLT-3 and Aurora kinase inhibitor, had received approval from the U.S. Food and Drug Administration (FDA). EP0042 is being advanced as a therapeutic option for acute myeloid leukemia (AML) and functions as an inhibitor targeting both FLT3 and Aurora kinase. This method is specifically tailored for AML patients who have developed a resistance to FLT3 inhibitors. Studies have indicated that the dual inhibition of FLT3 and Aurora kinase is capable of overcoming acquired resistance to selective FLT3 inhibition in both in vitro and in vivo settings.

Which Key Players Are Driving Competition In The Aurora Kinase B Market?

Major companies operating in the aurora kinase b market are Pfizer Inc., Johnson & Johnson, Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Sanofi SA, Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim International GmbH, Amgen Inc., Astellas Pharma Inc., Promega Corporation, Rigel Pharmaceuticals Inc., Tocris Bioscience, BPS Bioscience Inc., Advenchen Laboratories LLC, Shenzhen Chipscreen Biosciences Co. Ltd., Cyclacel Pharmaceuticals Inc., Sareum Holdings plc

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/aurora-kinase-b-global-market-report

Which Region Is Projected To Lead The Aurora Kinase B Market During The Forecast Period?

North America was the largest region in the aurora kinase B market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the aurora kinase b market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Aurora Kinase B Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=20496&type=smp

Browse Through More Reports Similar to the Global Aurora Kinase B Market 2026, By The Business Research Company

Cancer Biologics Market Report 2026

https://www.thebusinessresearchcompany.com/report/cancer-biologics-global-market-report

Skin Cancer Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/skin-cancer-drugs-global-market-report

Pancreatic Cancer Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/pancreatic-cancer-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

2025 Market Reports Update: Market Size Forecasts to 2034, Key Trends, Leading Players, and Top Regions – Get Ahead of the Competition Today!

Which Major Market Drivers Are Expected to Boost the Growth Potential of the Aurora Kinase B Market?

The aurora kinase B market is anticipated to expand due to the growing prevalence of cancer. Defined by the unchecked proliferation and dissemination of irregular cells, cancer can aggressively invade nearby tissues and spread to different body parts. The surge in cancer cases can be attributed to numerous factors, including an aging demographic, alterations in lifestyle, exposure to environmental risks, and advancements in detection and diagnosis methods. The aurora kinase B is instrumental in mitosis, and its excessive production is associated with chromosomal instability and the progression of cancer. Due to its significant role in tumor cell division, it is frequently the focus of cancer treatments. A report from the World Health Organization, the Switzerland-based intergovernmental body, revealed that an estimated 20 million new cancer incidents and 9.7 million deaths were recorded in 2022. The prediction for 2050 is over 35 million new cancer cases, marking a 77% rise from the 2022 figures. Consequently, the escalating rate of cancer is fueling the growth of the aurora kinase B market.

Get Your Free Sample Report Now – Explore Exclusive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20496&type=smp

#What is the Growth Potential of the Aurora Kinase B Market, and How Will It Perform by 2034?

In the past few years, the market size for aurora kinase b has seen a swift growth. Expecting to increase from $1.14 billion in 2024 to $1.27 billion in 2025, it is projected to experience a compound annual growth rate (CAGR) of 12.1%. Factors contributing to this expansion during the historic period include heightened demand for personalized cancer treatments, a global increase in cancer prevalence, increased investment in precision medicine, a rise in the number of clinical trials, and an uptick in governmental financial support for cancer research.

The market size for aurora kinase b is anticipated to experience a swift expansion in the coming years, reaching $1.99 billion in 2029 with a compound annual growth rate (CAGR) of 11.8%. The projected increase during this period is due to factors such as increased funding for innovative cancer treatment, a growing number of drug-resistant cancer cases, expanded research and development, a higher demand for combination therapies, and an increased incidence of solid tumors. The period’s major trends encompass technological progress, precision medicine, innovative therapies, data analysis, and novel treatments.

You can Directly Purchase the Report Here:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20496

What Are the Key Market Innovations in theAurora Kinase B Market Over the Coming Years?

Leading companies in the aurora kinase B market are introducing novel products such as aurora kinase inhibitors, mainly aimed at interrupting core processes in cell division. Aurora kinase inhibitors work by obstructing Aurora kinases, crucial for cell division, interrupting the multiplication of cancer cells, which may in turn potentially minimize tumor growth. In June 2023, for example, Ellipses Pharma, a biotechnology firm based in the UK, reported the approval of its EP0042, a dual FLT-3 and Aurora kinase inhibitor, by the U.S. Food and Drug Administration (FDA). EP0042 is under development as a remedy for acute myeloid leukemia (AML) and functions as an inhibitor targeting both FLT3 and Aurora kinase. This tactic is specifically designed for AML patients who have grown resistant to FLT3 inhibitors. Studies show that combined inhibition of FLT3 and Aurora kinase can effectively combat the acquired resistance to selective FLT3 inhibition both in laboratory and animal testing.

Who Are the Top Companies Driving Innovation and Growth in theAurora Kinase B Market?

Major companies operating in the aurora kinase B market are Pfizer Inc., Johnson & Johnson, Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Sanofi SA, Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim International GmbH, Amgen Inc., Astellas Pharma Inc., Promega Corporation, Rigel Pharmaceuticals Inc., Tocris Bioscience, BPS Bioscience Inc., Advenchen Laboratories LLC, Shenzhen Chipscreen Biosciences Co. Ltd., Cyclacel Pharmaceuticals Inc., Sareum Holdings plc

Order Your Report Now For A Swift Delivery:

https://www.thebusinessresearchcompany.com/report/aurora-kinase-b-global-market-report

Which Key Market Segments Comprise the Aurora Kinase B Market and Drive Its Revenue Growth?

The aurora kinase b market covered in this report is segmented –

1) By Type: AZD-2811, CS-2164, Danusertib, Ilorasertib, NMI-900, Other Types

2) By Application: Anaplastic Large Cell Lymphoma, Kidney Cancer, Lung Cancer, Prostate Cancer, Other Applications

3) By End-User: Hospitals, Research Institutes, Diagnostic Laboratories, Other End-Users

Subsegments:

1) By AZD-2811: Phase I Clinical Trials AZD-2811, Preclinical Development of AZD-2811, AZD-2811 in Combination Therapy, Targeted Cancer Treatment with AZD-2811

2) By CS-2164: Phase II Clinical Trials CS-2164, Preclinical Development of CS-2164, CS-2164 in Targeted Cancer Therapy, CS-2164 Combination Therapy in Clinical Studies

3) By Danusertib: Phase III Clinical Trials Danusertib, Danusertib for Hematological Malignancies, Danusertib for Solid Tumors, Combination Therapy with Danusertib

4) By Ilorasertib: Preclinical Development of Ilorasertib, Ilorasertib in Solid Tumor Treatment, Phase I and II Clinical Trials of Ilorasertib, Ilorasertib in Combination with Chemotherapies

5) By NMI-900: NMI-900 in Early-Stage Clinical Trials, NMI-900 for Targeted Cancer Therapy, Preclinical Studies of NMI-900, NMI-900 Combination Therapy Trials

6) By Other Types: Other Aurora Kinase B Inhibitors in Development, Novel Targeted Aurora Kinase B Drugs, Combination Therapies Involving Aurora Kinase B Inhibitors, Investigational Aurora Kinase B Inhibitors in Oncology

Gain Exclusive Market Insights—Customize Your Research Report Today for Fast Delivery!

https://www.thebusinessresearchcompany.com/customise?id=20496&type=smp

Which Regions Are Emerging as Leaders in the Aurora Kinase B Market?

North America was the largest region in the aurora kinase B market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the aurora kinase b market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Reports Similar to the Global Aurora Kinase B Market 2025, By The Business Research Company:

Cancer Biologics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/cancer-biologics-global-market-report

Skin Cancer Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/skin-cancer-drugs-global-market-report

Pancreatic Cancer Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/pancreatic-cancer-drugs-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

Get 15% OFF on all 2025 Global Market Reports until March 31st! Apply code FY25SAVE and grab your savings today!

What key factors are powering the surge in the aurora kinase b market right now?

In recent years, the market size for aurora kinase b has expanded swiftly. It is projected to balloon from $1.14 billion in 2024 to $1.27 billion in 2025, with a compound annual growth rate (CAGR) of 12.1%. Factors contributing to this growth during the historic period include heightened demand for targeted cancer treatments, a global surge in cancer prevalence, escalated investments in precision medicine, an increasing number of clinical trials, and enhanced government funding for cancer research.

How fast Is the aurora kinase b market expected to grow, and what’s its future value?

In the coming years, a swift expansion is anticipated in the market size of aurora kinase b, increasing to $1.99 billion in 2029, with a compound annual growth rate (CAGR) of 11.8%. The anticipated growth during the forecasted span can be credited to an increase in investments in cutting-edge cancer therapies, the surge in drug-resistant cancer cases, escalated research and development activities, intensifying demand for combination therapies, and the rising prevalence of solid tumors. Key trends projected for the forecast period involve technological innovations, precision medicine, new treatment methods, data analytics, and novel therapies.

Get your aurora kinase b market report here!

https://www.thebusinessresearchcompany.com/report/aurora-kinase-b-global-market-report

What are the leading drivers of growth in the aurora kinase b market?

The escalation of cancer prevalence is predicted to drive the expansion of the aurora kinase B market in the future. Cancer, which comprises a variety of diseases characterized by uncontrolled and abnormal cell growth that can infiltrate nearby tissues and spread to different body regions, is on the rise for a variety of reasons, including an aging population, lifestyle modifications, environmental risk factors, and enhanced diagnostic and detection methods. Aurora kinase B, crucial to the process of mitosis, becomes overexpressed, which can lead to chromosomal instability and the progression of cancer. As it is involved in tumor cell division, it is commonly a target in cancer treatments. For example, the World Health Organization, a Switzerland-based international organization, reported in February 2024 that an estimated 20 million new cancer cases arose in 2022, resulting in 9.7 million deaths. By 2050, the number of new cancer cases is projected to surpass 35 million, a 77% increase from 2022 figures. Consequently, the escalating prevalence of cancer is fueling the growth of the aurora kinase B market.

What are the key segments defining the aurora kinase b market?

The aurora kinase b market covered in this report is segmented –

1) By Type: AZD-2811, CS-2164, Danusertib, Ilorasertib, NMI-900, Other Types

2) By Application: Anaplastic Large Cell Lymphoma, Kidney Cancer, Lung Cancer, Prostate Cancer, Other Applications

3) By End-User: Hospitals, Research Institutes, Diagnostic Laboratories, Other End-Users

Subsegments:

1) By AZD-2811: Phase I Clinical Trials AZD-2811, Preclinical Development of AZD-2811, AZD-2811 in Combination Therapy, Targeted Cancer Treatment with AZD-2811

2) By CS-2164: Phase II Clinical Trials CS-2164, Preclinical Development of CS-2164, CS-2164 in Targeted Cancer Therapy, CS-2164 Combination Therapy in Clinical Studies

3) By Danusertib: Phase III Clinical Trials Danusertib, Danusertib for Hematological Malignancies, Danusertib for Solid Tumors, Combination Therapy with Danusertib

4) By Ilorasertib: Preclinical Development of Ilorasertib, Ilorasertib in Solid Tumor Treatment, Phase I and II Clinical Trials of Ilorasertib, Ilorasertib in Combination with Chemotherapies

5) By NMI-900: NMI-900 in Early-Stage Clinical Trials, NMI-900 for Targeted Cancer Therapy, Preclinical Studies of NMI-900, NMI-900 Combination Therapy Trials

6) By Other Types: Other Aurora Kinase B Inhibitors in Development, Novel Targeted Aurora Kinase B Drugs, Combination Therapies Involving Aurora Kinase B Inhibitors, Investigational Aurora Kinase B Inhibitors in Oncology

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20496&type=smp

Who are the key players steering the development of the aurora kinase b market?

Major companies operating in the aurora kinase B market are Pfizer Inc., Johnson & Johnson, Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Sanofi SA, Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim International GmbH, Amgen Inc., Astellas Pharma Inc., Promega Corporation, Rigel Pharmaceuticals Inc., Tocris Bioscience, BPS Bioscience Inc., Advenchen Laboratories LLC, Shenzhen Chipscreen Biosciences Co. Ltd., Cyclacel Pharmaceuticals Inc., Sareum Holdings plc

What emerging trends are influencing the growth of the aurora kinase b market?

Noteworthy firms in the aurora kinase B market are inventing unique products such as aurora kinase inhibitors, aimed at targeting and disrupting key cellular division processes. Aurora kinase inhibitors are medications conceived to impede the functions of Aurora kinases, vital for cell division, thus curbing cancer cell propagation and potentially minimizing tumor expansion. For instance, in June 2023, a biotech company based in the UK, Ellipses Pharma, received approval from the U.S. Food and Drug Administration (FDA) for its product EP0042, a twin FLT-3 and Aurora kinase inhibitor. EP0042 is currently under development as a remedy for acute myeloid leukemia (AML), functioning as an inhibitor that targets both FLT3 and Aurora kinase. This strategy is exclusively designed for AML sufferers who have developed immunity against FLT3 inhibitors. Studies have shown that a combined obstruction of FLT3 and Aurora kinase can circumvent acquired resistance to selective FLT3 inhibition both in vitro and in vivo.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20496

Which regions are most influential in expanding the aurora kinase b market?

North America was the largest region in the aurora kinase B market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the aurora kinase b market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Similar Reports By The Business Research Company:

Cancer Biologics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/cancer-biologics-global-market-report

Skin Cancer Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/skin-cancer-drugs-global-market-report

Pancreatic Cancer Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/pancreatic-cancer-drugs-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

What Growth Opportunities are Expected to Drive the Aurora Kinase B Market’s CAGR Through 2034?

The market size for aurora kinase b has experienced swift expansion in the last few years. Expected to increase from $1.14 billion in 2024 to $1.27 billion in 2025, this market will grow at a compound annual growth rate (CAGR) of 12.1%. Factors contributing to this growth during the historical period include an increased demand for specific cancer treatments, a global rise in cancer cases, escalated investments in precision medicine, and an increase in both the number of clinical trials, and governmental funding for cancer research.

In the coming years, the market size of aurora kinase b is predicted to experience swift expansion, with an estimated worth of $1.99 billion in 2029 and a compound annual growth rate (CAGR) of 11.8%. This surge within the forecasted period is anticipated due to an increase in funding for cutting-edge cancer treatments, the escalating occurrence of drug-resistant cancers, augmented research and development efforts, a growing demand for combination therapies, and a rising prevalence of firm tumors. Foreseen trends for the period include progress in technology, precision-oriented medication, innovative treatment methodologies, data analytics, and unique therapies.

What Industry-Specific Factors Are Fueling the Growth of the Aurora Kinase B Market?

The upward trend in cancer cases is predicted to fuel the expansion of the aurora kinase B market. Cancer is a collection of diseases defined by uncontrolled proliferation and dispersion of abnormal cells, which can intrude on nearby tissues and spread to other body parts. The increase in cancer cases can be attributed to factors like aging population, shifts in lifestyle, environmental exposure, and advancements in detection and diagnosis. Aurora kinase B has a vital function in mitosis, and its overproduction is associated with chromosomal instability and the advancement of cancer. Due to its role in the division of tumor cells, it is regularly targeted in cancer treatments. The World Health Organization, a Swiss intergovernmental organization, reported in February 2024, that approximately 20 million new cancer cases and 9.7 million deaths occurred in 2022. By 2050, it is anticipated that new cancer instances will surpass 35 million, marking a 77% rise from 2022. Hence, the increasing prevalence of cancer is reinforcing the growth of the aurora kinase B market.

Request Your Free Aurora Kinase B Market Report Sample Now!

https://www.thebusinessresearchcompany.com/sample.aspx?id=20496&type=smp

What Are the Leading Industry Players Dominating the Aurora Kinase B Market?

Major companies operating in the aurora kinase B market are:

• Pfizer Inc._x000D_

• Johnson & Johnson_x000D_

• Roche Holding AG_x000D_

• Merck & Co. Inc._x000D_

• AbbVie Inc._x000D_

What Are the Latest Trends Leading to Disruption in the Aurora Kinase B Market?

Key players in the Aurora kinase B industry are focusing their efforts on the creation of advanced products, notably aurora kinase inhibitors, which are specifically devised to interfere with crucial cell division processes. These inhibitor drugs are engineered to impede the tasks of Aurora kinases, pivotal for cell division, hence interrupting the multiplication of cancer cells and potentially diminishing tumor growth. For example, Ellipses Pharma, a biotech firm based in the UK, received approval from the U.S. Food and Drug Administration (FDA) in June 2023 for its dual FLT-3 and Aurora kinase inhibitor, EP0042. This drug is under development to treat acute myeloid leukemia (AML) by inhibiting both FLT3 and Aurora kinase, specifically devised for patients who have grown resistant to FLT3 inhibitors. Studies show that combined inhibition of FLT3 and Aurora kinase can beat the acquired resistance to targeted FLT3 inhibition, in both lab settings and living organisms.

Get Instant Access to the Global Aurora Kinase B Market Report with Swift Delivery!

https://www.thebusinessresearchcompany.com/report/aurora-kinase-b-global-market-report

What Are the Strategic Segments Comprising the Aurora Kinase B Market and Their Growth Contributions?

The aurora kinase b market covered in this report is segmented –

1) By Type: AZD-2811, CS-2164, Danusertib, Ilorasertib, NMI-900, Other Types

2) By Application: Anaplastic Large Cell Lymphoma, Kidney Cancer, Lung Cancer, Prostate Cancer, Other Applications

3) By End-User: Hospitals, Research Institutes, Diagnostic Laboratories, Other End-Users

Subsegments:

1) By AZD-2811: Phase I Clinical Trials AZD-2811, Preclinical Development of AZD-2811, AZD-2811 in Combination Therapy, Targeted Cancer Treatment with AZD-2811

2) By CS-2164: Phase II Clinical Trials CS-2164, Preclinical Development of CS-2164, CS-2164 in Targeted Cancer Therapy, CS-2164 Combination Therapy in Clinical Studies

3) By Danusertib: Phase III Clinical Trials Danusertib, Danusertib for Hematological Malignancies, Danusertib for Solid Tumors, Combination Therapy with Danusertib

4) By Ilorasertib: Preclinical Development of Ilorasertib, Ilorasertib in Solid Tumor Treatment, Phase I and II Clinical Trials of Ilorasertib, Ilorasertib in Combination with Chemotherapies

5) By NMI-900: NMI-900 in Early-Stage Clinical Trials, NMI-900 for Targeted Cancer Therapy, Preclinical Studies of NMI-900, NMI-900 Combination Therapy Trials

6) By Other Types: Other Aurora Kinase B Inhibitors in Development, Novel Targeted Aurora Kinase B Drugs, Combination Therapies Involving Aurora Kinase B Inhibitors, Investigational Aurora Kinase B Inhibitors in Oncology

Which Regions Are Significant to the Growth of the Aurora Kinase B Market?

North America was the largest region in the aurora kinase B market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the aurora kinase b market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

How Can We Define the Aurora Kinase B Market and Its Key Components?

Aurora kinase B is a protein enzyme that plays a critical role in cell division, particularly during mitosis. It is involved in regulating chromosome alignment, segregation, and the proper distribution of genetic material to daughter cells. Aurora kinase B is essential for maintaining genomic stability, and its dysregulation is often associated with various cancers.

Browse Through More Similar Reports By The Business Research Company:

Cancer Biologics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/cancer-biologics-global-market-report

Skin Cancer Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/skin-cancer-drugs-global-market-report

Pancreatic Cancer Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/pancreatic-cancer-drugs-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: